Kobayashi H, Moniwa N, Gotoh J, Sugimura M, Terao T
Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Shizuoka, Japan.
Cancer Res. 1994 Jan 1;54(1):261-7.
The present study was undertaken to investigate the role of plasminogen activator inhibitor type 1 (PAI-1) and activated protein C (APC) in the regulation of tumor cell invasion. PAI-1 was purified in active form from conditioned medium of human umbilical vein endothelial cells under denaturing conditions (4 M guanidine-HCl). The purified inhibitor reacts with urokinase-type plasminogen activator (uPA) and APC. Two selected human lines, HOC-I (ovarian cancer cells) and SMT-ccl (choriocarcinoma cells), preferentially invaded through reconstituted basement membranes in an in vitro invasion assay using a modified Boyden chamber. The present study determined the efficacy of these two agents (PAI-1 and APC) used alone or in combination in inhibiting or facilitating tumor cell invasion. Active PAI-1 inhibited the tumor cell surface receptor-bound uPA activity. In an in vitro invasion assay, active PAI-1 reduced tumor cell invasive potential in a dose-dependent manner. When SMT-ccl cells saturated with uPA-PAI-1 complexes were treated with a 50-fold molar excess of APC, PAI-1-APC complex was demonstrated in conditioned medium, indicating that PAI-1 was dissociated from receptor-bound uPA on tumor cells and that tumor cell-associated uPA restored its enzymatic activity. Although APC alone had no effect on tumor cell invasion, the addition of APC to the cells saturated with uPA-PAI-1 complexes showed regeneration of tumor cell surface receptor-bound uPA activity and produced substantial and efficient invading effects. These data suggest that PAI-1 activity may be neutralized by APC or that APC may promote tumor cell invasion via inactivation of PAI-1 by formation of a stable PAI-1-APC complex. These observations suggest that APC may play a critical role in the initiation of a hematogenous metastatic process (extravasation step).
本研究旨在探讨1型纤溶酶原激活物抑制剂(PAI-1)和活化蛋白C(APC)在肿瘤细胞侵袭调控中的作用。在变性条件(4M盐酸胍)下,从人脐静脉内皮细胞的条件培养基中以活性形式纯化PAI-1。纯化的抑制剂可与尿激酶型纤溶酶原激活物(uPA)和APC反应。在使用改良的博伊登室进行的体外侵袭试验中,两种选定的人类细胞系HOC-I(卵巢癌细胞)和SMT-ccl(绒毛膜癌细胞)优先穿过重组基底膜。本研究确定了单独使用或联合使用这两种药物(PAI-1和APC)抑制或促进肿瘤细胞侵袭的效果。活性PAI-1抑制肿瘤细胞表面受体结合的uPA活性。在体外侵袭试验中,活性PAI-1以剂量依赖的方式降低肿瘤细胞的侵袭潜能。当用50倍摩尔过量的APC处理饱和有uPA-PAI-1复合物的SMT-ccl细胞时,在条件培养基中检测到PAI-1-APC复合物,这表明PAI-1从肿瘤细胞上与受体结合的uPA上解离,并且肿瘤细胞相关的uPA恢复了其酶活性。虽然单独的APC对肿瘤细胞侵袭没有影响,但向饱和有uPA-PAI-1复合物的细胞中添加APC显示肿瘤细胞表面受体结合的uPA活性再生,并产生显著且有效的侵袭作用。这些数据表明PAI-1活性可能被APC中和,或者APC可能通过形成稳定的PAI-1-APC复合物使PAI-1失活来促进肿瘤细胞侵袭。这些观察结果表明APC可能在血行转移过程的起始(外渗步骤)中起关键作用。